novo nordisk semaglutide clinical trials FLOW Trial (funded by Nordisk): showed 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators Novo Nordisk justifies reasoning behind

You can self-inject the drug into your abdomen or thigh

Garvey WT, Frias JP, Jastreboff AM et al (2023) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

PlexusDx maps 14 distinct peptide-pathway mechanisms across 49 biomarkers and 150+ genetic insights specific to your body's weight regulation

Yet, it seems like the microdoses people are taking as part of this fad are a small fraction of even the lowest doses that the drug companies already tested carefully last decade

However, dedicated cardiovascular outcomes trials (CVOTs) for retatrutide have not yet been completed , and it is not yet confirmed whether a CVOT is registered as part of the current TRIUMPH Phase 3 programme

Meet with your doctor via video to review health history and goals